EUCTR2009-009756-21-IT进行中（未招募）不适用
A Single-arm, Multicenter, Proof-of-concept Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects with Elevated Serum Calcium Despite Recent Treatment with IV Bisphosphonates - ND
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- Amgen Inc
- 入组人数
- 33
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Hypercalcemia of Malignancy (HCM) as defined as documented histologically or cytologically confirmed cancer and a CSC > 12.5 mg/dL (3.1 mmol/L) at screening by local laboratory - Last IV bisphosphonate treatment must be ≥ 7 days and ≤ 30 days before the screening CSC -Adults (≥ 18 years) -Adequate organ function as defined by the following criteria: - serum aspartate aminotransferase (AST) ≤ 5 x upper limit of normal (ULN) - serum alanine aminotransferase (ALT) ≤ 5 x ULN - serum total bilirubin ≤ 2 x ULN -Before any study-specific procedure is performed, the appropriate written informed consent must be obtained
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Evidence of hyperparathyroidism, hyperthyroidism, adrenal insufficiency, vitamin D intoxication, milk alkali syndrome, sarcoidosis, or other granulomatous disease Receiving dialysis for renal failure Prior history or current evidence of osteonecrosis/osteomyelitis of the jaw Active dental or jaw condition which requires oral surgery Non-healed dental/oral surgery Planned invasive dental procedure over the course of the study Prior administration of denosumab Treatment with thiazides, calcitonin, mithramycin, and gallium nitrate within 7 days prior to the date of the screening CSC Treatment with cinacalcet within 4 weeks prior to the date of the screening CSC Thirty days or less since receiving an investigational product or device (ie, does not have marketing authorization; thalidomide use is allowed) in another clinical study Known sensitivity to any of the products to be administered during the study (eg, mammalian derived products) Female subject is pregnant or breast feeding, or planning to become pregnant within 7 months after the end of treatment Subject (male or female) is not willing to use 2 highly effective methods of contraception during treatment and for 7 months (female) or 10 months (male) after the end of treatment Male subject with a pregnant partner who is not willing to use a condom during treatment and for additional 10 months after the end of treatment Subject will not be available for follow-up assessment. Any organic or psychiatric disorder that, in the opinion of the investigator, might prevent the subject from completing the study or interfere with the interpretation of the study results
研究者
相似试验
进行中（未招募）
不适用
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum CalciumHypercalcemia of malignancy (HCM)MedDRA version: 15.0Level: LLTClassification code 10020588Term: Hypercalcemia of malignancySystem Organ Class: 10014698 - Endocrine disordersEUCTR2009-009756-21-PLAmgen Inc33
进行中（未招募）
1 期
A Single-arm, Multicenter, Proof-of-concept Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects with Elevated Serum Calcium Despite Recent Treatment with IV Bisphosphonates.EUCTR2009-009756-21-FRAmgen Inc33
进行中（未招募）
不适用
A multicenter, single arm, proof of concept study to investigate in a first stage the efficacy of a combination therapy of Sandostatin® LAR® and Cabergoline, optionally followed by a combination of Sandostatin® LAR® and pegvisomant, in acromegalic patients only partially responsive to somatostatin analog monotherapy - PHOENIXMedDRA version: M15Level: LLTClassification code 10000599acromegalyEUCTR2005-002919-24-DEovartis Pharma GmbH100
已完成
3 期
A study to assess Efficacy and safety of Ayurvedic Kadha in health and immunity related parameters in mild COVID-19 patients.CTRI/2021/03/032072MARC Laboratories Ltd50
尚未招募
不适用
A prospective, single-arm, multicenter, investigator-initiated, interventional study to evaluate the efficacy and safety of switching from low- and moderate-intensity statin to Ezetimibe 10 mg and ROsuvastatIn 2.5 mg CombinAtion therapy in patients with type 2 diabetes mellitus with dyslipidemia. (EROICA)KCT0008224Hanyang University Guri Hospital665